Insiders At Intellia Therapeutics Sold US$975k In Stock, Alluding To Potential Weakness
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $45
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $12
Express News | Goldman Sachs Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $12
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $40 to $45
